![](/img/cover-not-exists.png)
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Y. Brandberg, S. Aamdal, L. Bastholt, M. Hernberg, U. Stierner, H. von der Maase, J. HanssonVolume:
48
Year:
2012
Language:
english
Pages:
1
DOI:
10.1016/j.ejca.2011.11.019
File:
PDF, 419 KB
english, 2012